PE20080973A1 - Derivados de 5,7-disustituidos[1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona - Google Patents
Derivados de 5,7-disustituidos[1,3]tiazolo[4,5-d]pirimidin-2(3h)-onaInfo
- Publication number
- PE20080973A1 PE20080973A1 PE2007001323A PE2007001323A PE20080973A1 PE 20080973 A1 PE20080973 A1 PE 20080973A1 PE 2007001323 A PE2007001323 A PE 2007001323A PE 2007001323 A PE2007001323 A PE 2007001323A PE 20080973 A1 PE20080973 A1 PE 20080973A1
- Authority
- PE
- Peru
- Prior art keywords
- thiazolo
- pyrimidin
- hydroximethyl
- thio
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
Abstract
SE REFIERE A UN COMPUESTO I, DONDE R1 ES CH3 O CF3; R2 ES HALO, CN, ALQUILO C1-C6; R3 Y R4 SON CADA UNO H, CH3; n ES DE 0-2. SON COMPUESTOS PREFERIDOS: 5-{[(1S)-1-(5-FLUOROPIRIDIN-2-IL)ETIL]TIO}-7-{[(1R)-1-(HIDROXIMETIL)-3-METILBUTIL]AMINO}[1,3]TIAZOLO[4,5-d]PIRIMIDIN-2(3H)-ONA; 5-{[1-(3-FLUOROPIRIDIN-4-IL)ETIL]TIO}-7-{[(1R)-1-(HIDROXIMETIL)-3-METILBUTIL]AMINO}[1,3]TIAZOLO[4,5-d]PIRIMIDIN-2(3H)-ONA; 5-{[(1S)-1-(6-CLOROPIRIDIN-3-IL)ETIL]TIO}-7-{[(1R)-1-(HIDROXIMETIL)BUTIL](METIL)AMINO[1,3]TIAZOLO[4,5-d]PIRIMIDIN-2(3H)-ONA; ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES DE UTILIDAD EN EL TRATAMIENTO DE TRANSTORNOS NEURODEGENERATIVOS CEREBROVASCULARES, ENFERMEDADES DESMIELINIZANTES Y ENFERMEDADES PULMONARES
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82746006P | 2006-09-29 | 2006-09-29 | |
US82812506P | 2006-10-04 | 2006-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20080973A1 true PE20080973A1 (es) | 2008-10-02 |
Family
ID=39230456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007001323A PE20080973A1 (es) | 2006-09-29 | 2007-09-28 | Derivados de 5,7-disustituidos[1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona |
Country Status (22)
Country | Link |
---|---|
US (2) | US7960395B2 (es) |
EP (1) | EP2069364B1 (es) |
JP (1) | JP5422386B2 (es) |
KR (1) | KR101345085B1 (es) |
AR (1) | AR063023A1 (es) |
AT (1) | ATE537177T1 (es) |
AU (1) | AU2007300748B2 (es) |
BR (1) | BRPI0717109A2 (es) |
CA (1) | CA2664789A1 (es) |
CL (1) | CL2007002813A1 (es) |
CO (1) | CO6150165A2 (es) |
ES (1) | ES2377469T3 (es) |
HK (1) | HK1131389A1 (es) |
IL (1) | IL197293A0 (es) |
MX (1) | MX2009003005A (es) |
NO (1) | NO20091579L (es) |
NZ (1) | NZ576520A (es) |
PE (1) | PE20080973A1 (es) |
RU (1) | RU2441012C2 (es) |
TW (1) | TW200820973A (es) |
UY (1) | UY30612A1 (es) |
WO (1) | WO2008039138A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR071036A1 (es) * | 2008-03-26 | 2010-05-19 | Astrazeneca Ab | Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1. |
TWI543975B (zh) | 2011-09-13 | 2016-08-01 | Eisai R&D Man Co Ltd | Pyrrolidin-3-yl acetic acid derivatives |
US8476301B2 (en) | 2011-09-13 | 2013-07-02 | Eisai R&D Management Co., Ltd. | Pyrrolidin-3-ylacetic acid derivative |
BR112015021848A2 (pt) | 2013-03-12 | 2020-02-11 | Eisai R&D Man Co Ltd | sal de derivado do ácido pirrolidin-3-il acético e cristais do mesmo |
GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9802729D0 (sv) | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
EP1257555B1 (en) | 2000-02-11 | 2003-12-03 | AstraZeneca AB | Pyrimidine compounds and their use as modulators of chemokine receptor activity |
SE0101082D0 (sv) * | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
GB0221829D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
WO2005033115A1 (en) | 2003-10-07 | 2005-04-14 | Astrazeneca Ab | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 |
EP1844054A2 (en) * | 2004-12-17 | 2007-10-17 | AstraZeneca AB | Thiazolopyrimidine compounds for the modulation of chemokine receptor activity |
AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
-
2007
- 2007-09-21 TW TW096135626A patent/TW200820973A/zh unknown
- 2007-09-27 EP EP07835061A patent/EP2069364B1/en active Active
- 2007-09-27 WO PCT/SE2007/000857 patent/WO2008039138A1/en active Application Filing
- 2007-09-27 RU RU2009109100/04A patent/RU2441012C2/ru not_active IP Right Cessation
- 2007-09-27 AT AT07835061T patent/ATE537177T1/de active
- 2007-09-27 US US11/862,743 patent/US7960395B2/en active Active
- 2007-09-27 UY UY30612A patent/UY30612A1/es not_active Application Discontinuation
- 2007-09-27 BR BRPI0717109-9A patent/BRPI0717109A2/pt not_active IP Right Cessation
- 2007-09-27 MX MX2009003005A patent/MX2009003005A/es active IP Right Grant
- 2007-09-27 CA CA002664789A patent/CA2664789A1/en not_active Abandoned
- 2007-09-27 JP JP2009530308A patent/JP5422386B2/ja active Active
- 2007-09-27 KR KR1020097006362A patent/KR101345085B1/ko not_active IP Right Cessation
- 2007-09-27 AU AU2007300748A patent/AU2007300748B2/en not_active Ceased
- 2007-09-27 ES ES07835061T patent/ES2377469T3/es active Active
- 2007-09-27 AR ARP070104275A patent/AR063023A1/es not_active Application Discontinuation
- 2007-09-27 NZ NZ576520A patent/NZ576520A/en unknown
- 2007-09-28 PE PE2007001323A patent/PE20080973A1/es not_active Application Discontinuation
- 2007-09-28 CL CL200702813A patent/CL2007002813A1/es unknown
-
2009
- 2009-02-26 IL IL197293A patent/IL197293A0/en unknown
- 2009-03-05 CO CO09022856A patent/CO6150165A2/es unknown
- 2009-04-21 NO NO20091579A patent/NO20091579L/no not_active Application Discontinuation
- 2009-11-26 HK HK09111033.7A patent/HK1131389A1/xx not_active IP Right Cessation
-
2011
- 2011-01-19 US US13/009,384 patent/US20110105537A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2377469T3 (es) | 2012-03-27 |
CO6150165A2 (es) | 2010-04-20 |
AU2007300748A1 (en) | 2008-04-03 |
AU2007300748B2 (en) | 2011-09-08 |
US7960395B2 (en) | 2011-06-14 |
AR063023A1 (es) | 2008-12-23 |
RU2441012C2 (ru) | 2012-01-27 |
EP2069364A4 (en) | 2010-03-24 |
BRPI0717109A2 (pt) | 2013-10-08 |
KR20090057069A (ko) | 2009-06-03 |
HK1131389A1 (en) | 2010-01-22 |
EP2069364B1 (en) | 2011-12-14 |
JP5422386B2 (ja) | 2014-02-19 |
US20110105537A1 (en) | 2011-05-05 |
UY30612A1 (es) | 2008-05-02 |
EP2069364A1 (en) | 2009-06-17 |
US20080318981A1 (en) | 2008-12-25 |
NZ576520A (en) | 2011-08-26 |
MX2009003005A (es) | 2009-04-01 |
IL197293A0 (en) | 2009-12-24 |
WO2008039138A8 (en) | 2009-03-19 |
JP2010504962A (ja) | 2010-02-18 |
RU2009109100A (ru) | 2010-11-10 |
WO2008039138A1 (en) | 2008-04-03 |
ATE537177T1 (de) | 2011-12-15 |
CL2007002813A1 (es) | 2008-04-04 |
CA2664789A1 (en) | 2008-04-03 |
KR101345085B1 (ko) | 2013-12-31 |
NO20091579L (no) | 2009-04-21 |
TW200820973A (en) | 2008-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20070531A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas | |
PE20080931A1 (es) | Imidazopirazinas como inhibidores de proteina quinasa | |
CA2523261A1 (en) | Fused pyrimidine derivatives with crf activity | |
CY1109069T1 (el) | Ενωσεις ιμιδαζοπυριδαζινης | |
PE20120505A1 (es) | Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a | |
PE20080772A1 (es) | Nuevos derivados de bipiridina sustituidos y su uso | |
TW200714605A (en) | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives | |
PE20080114A1 (es) | Derivados de heteroarilo biciclicos como moduladores del receptor canabinoide | |
ATE430744T1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
TW200612936A (en) | Indole derivatives | |
AR037647A1 (es) | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina | |
PE20090674A1 (es) | Compuestos multiciclicos | |
UY29301A1 (es) | Derivados amida | |
ATE446962T1 (de) | Thiazolopyridinon-derivate als mch- rezeptorantagonisten | |
UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
EA200401194A1 (ru) | Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение | |
NO20081924L (no) | 7-[2-[4-(6-fluor-3-metyl-1,2-benzisoksazol-5-yl)-1-pipera-zinyl]etyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amin | |
PE20090648A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
PE20080973A1 (es) | Derivados de 5,7-disustituidos[1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona | |
PE20071090A1 (es) | 5-pirazolpiperidinas-(sustituidas) | |
BRPI0517412A (pt) | derivados de benzodiazepina substituìdos | |
TW200720279A (en) | Novel 5,7-disubstituted [1,3]thiazolo[4,5-D]pyrimidin-2(3H)-one derivatives | |
ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten | |
PE20060585A1 (es) | Derivados de 2-amido-4-feniltiazol como antagonistas de quimiocinas y su preparacion | |
AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |